Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) prevent ER-positive breast cancers but not ER-negative or triple-negative breast cancers (TNBCs).
• Nuclear estrogen receptor (ER) pathways are key targets for breast cancer prevention.

Purpose of the Study:

• To evaluate the efficacy of nuclear retinoid X receptor (RXR) agonists, IRX4204 and 9cUAB30, in preventing ER-negative and triple-negative breast cancer (TNBC) development.
• To explore novel therapeutic strategies for TNBC prevention beyond ER-targeted therapies.

Main Methods:

• Testing RXR agonists IRX4204 and 9cUAB30 in three ER-negative mouse models: MMTV-ErbB2, C3(1)/SV40-TAg, and Brca1-deficient.
• Assessing tumor formation delay, incidence, and survival rates in treated versus vehicle-controlled groups.
• Biomarker analysis including Ki-67 expression and cytotoxic T-cell infiltration.

Main Results:

• IRX4204 significantly delayed mammary tumor formation in all three ER-negative mouse models with modest toxicities.
• Complete prevention of mammary tumors was observed in some MMTV-ErbB2 mice treated with IRX4204.
• IRX4204 treatment led to decreased Ki-67 expression and increased cytotoxic T-cell infiltration in delayed tumors.
• 9cUAB30 also delayed tumor formation in Brca1-deficient mice, though to a lesser extent than IRX4204.

Conclusions:

• RXR agonists, particularly IRX4204, demonstrate significant pre-clinical efficacy in preventing ER-negative and triple-negative breast cancer development.
• The findings support further investigation of RXR agonists as a prophylactic strategy for TNBC.
• Modulation of tumor cell proliferation (Ki-67) and immune response (T-cells) are potential mechanisms underlying RXR agonist efficacy.